- FDA approves vorasidenib for Grade 2 astrocytoma or ...🔍
- Servier's VORANIGO® 🔍
- New therapy for glioma receives FDA approval🔍
- FDA approves new therapy for glioma patients for first time in decades🔍
- FDA approves first IDH|targeted glioma drug🔍
- Vorasidenib Breaks Through as the First Systemic Therapy for ...🔍
- FDA Approves Vorasidenib🔍
- Vorasidenib Secures FDA Approval in IDH|Mutant Diffuse Glioma🔍
FDA Approves Vorasidenib
FDA approves vorasidenib for Grade 2 astrocytoma or ...
On August 6, 2024, the Food and Drug Administration approved vorasidenib (Voranigo, Servier Pharmaceuticals LLC), an isocitrate ...
Servier's VORANIGO® (vorasidenib) tablets receives FDA approval ...
VORANIGO is available and offers glioma patients the ability to actively manage their disease with the convenience of a once-daily pill.
VORANIGO (vorasidenib), FDA Approved for the Treatment of ...
Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease, was selected by Servier as a limited ...
New therapy for glioma receives FDA approval - Duke Neurosurgery
The FDA has approved a new targeted drug specifically for brain tumors called low-grade gliomas. The drug, vorasidenib, was shown in clinical trials to delay ...
FDA approves new therapy for glioma patients for first time in decades
Vorasidenib has been approved by the US Food and Drug Administration (FDA) for patients with Grade 2 gliomas with IDH1 or IDH2 mutations.
FDA approves first IDH-targeted glioma drug | Nature Biotechnology
Voranigo (vorasidenib), made by French drugmaker Servier Pharmaceuticals, was approved in August by the US Food and Drug Administration.
Vorasidenib Breaks Through as the First Systemic Therapy for ...
Seema Nagpal, MD, discusses the significance of the FDA approval of vorasidenib for adult and pediatric patients with IDH1/2-mutant glioma.
FDA Approves Vorasidenib, a New Treatment for Low-Grade Gliomas
In clinical studies, vorasidenib showed remarkable results. It reduced the risk of the tumor getting worse or causing death by 61%. This is a significant ...
Vorasidenib Secures FDA Approval in IDH-Mutant Diffuse Glioma
The FDA has granted approval to vorasidenib for the treatment of patients with IDH-mutant diffuse glioma.
FDA Approves Companion Diagnostic To Identify Patients With ...
The FDA approved the Ion Torrent Oncomine Dx Target Test for identifying patients eligible for vorasidenib treatment.
FDA approves IDH1 and IDH2 inhibitor for brain cancer - Nature
The FDA approved Servier's IDH1 and IDH2 inhibitor vorasidenib (Voranigo) for IDH-mutant glioma following surgery, providing the first new drug in decades for ...
FDA Approves Vorasidenib for IDH1/2+ Grade 2 Astrocytoma or ...
The FDA has approved vorasidenib for grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.
Vorasidenib Approved by FDA for Grade 2 IDH-Mutant Glioma
Vorasidenib becomes the first targeted therapy for grade 2 isocitrate dehydrogenase (IDH)–mutant glioma to receive FDA approval.
VORANIGO® (vorasidenib) tablets, for oral use - accessdata.fda.gov
An FDA-approved test for detection of IDH1 or IDH2 mutations in Grade 2 astrocytoma or oligodendroglioma for selecting patients for treatment with VORANIGO is ...
FDA Approves Companion Diagnostic for Vorasidenib in IDH-Mutant ...
Vorasidenib, a selective inhibitor of mutant IDH1/IDH2, is FDA-approved for patients 12 and older with IDH-mutant grade 2 glioma. The FDA has ...
Vorasidenib secures FDA approval in IDH-mutant diffuse glioma
The United States Food and Drug Administration (FDA), which has responsibility for protecting and promoting US public health, has approved ...
FDA Approves Vorasidenib in IDH+ Astrocytoma/Oligodendroglioma
Phase 3 data from the INDIGO trial support the FDA approval of vorasidenib for select patients with grade 2 astrocytoma or ...
FDA Approves Vorasidenib for Certain Gliomas - Medscape
FDA Approves First Targeted Therapy for Gliomas With IDH Mutations ... The US Food and Drug Administration (FDA) has approved vorasidenib ( ...
FDA approves brain cancer therapy that relies on Johns Hopkins ...
The drug, called vorasidenib, is a targeted cancer therapy that works by inhibiting the activity of a mutated gene called IDH, slowing the growth of the cancer.
Vorasidenib approved by FDA for treatment of IDH-mutant gliomas
A new drug for treatment of a type of brain cancer, called IDH-mutant low-grade glioma, was approved Aug. 6 by the U.S. Food and Drug ...